IDN5109, a taxane with oral bioavailability and potent antitumor activity

Maria Ines Nicoletti, Tina Colombo, Cosmo Rossi, Caterina Monardo, Stefania Stura, Massimo Zucchetti, Antonella Riva, Paolo Morazzoni, Maria Benedetta Donati, Ezio Bombardelli, Maurizio D'Incalci, Raffaella Giavazzi

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

IDN5109 is a new taxane, derived from 14β-hydroxy-10-deacetylbaccatin III, selected for its lack of cross-resistance in tumor cell lines expressing the multidrug resistant phenotype. Because, unlike paclitaxel, IDN5109 is a poor substrate for P-glycoprotein, we hypothesized that IDN5109 given p.o. could improve bioavailability compared with paclitaxel. Here, we studied the p.o. and i.v. pharmacokinetics of IDN5109 together with its antitumor activity. Using a high-performance liquid chromatography method, the bioavailability of IDN5109 was determined to be 48% after oral delivery. IDN5109 given p.o. was highly active against the two human ovarian carcinoma xenografts 1A9 and HOC18 (90-100% tumor regressions) and showed significant activity on the paclitaxel-resistant MNB-PTX1 xenograft (10% tumor regressions). The p.o. administration was as active as the i.v. route at doses reflecting the pharmacokinetic data. IDN5109 is the first taxane with good oral bioavailability and potent antitumor activity and represents a potential candidate for clinical investigation.

Original languageEnglish
Pages (from-to)842-846
Number of pages5
JournalCancer Research
Volume60
Issue number4
Publication statusPublished - Feb 15 2000

Fingerprint

Paclitaxel
Biological Availability
Heterografts
Pharmacokinetics
P-Glycoprotein
Tumor Cell Line
High Pressure Liquid Chromatography
Carcinoma
Phenotype
taxane
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nicoletti, M. I., Colombo, T., Rossi, C., Monardo, C., Stura, S., Zucchetti, M., ... Giavazzi, R. (2000). IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Research, 60(4), 842-846.

IDN5109, a taxane with oral bioavailability and potent antitumor activity. / Nicoletti, Maria Ines; Colombo, Tina; Rossi, Cosmo; Monardo, Caterina; Stura, Stefania; Zucchetti, Massimo; Riva, Antonella; Morazzoni, Paolo; Donati, Maria Benedetta; Bombardelli, Ezio; D'Incalci, Maurizio; Giavazzi, Raffaella.

In: Cancer Research, Vol. 60, No. 4, 15.02.2000, p. 842-846.

Research output: Contribution to journalArticle

Nicoletti, MI, Colombo, T, Rossi, C, Monardo, C, Stura, S, Zucchetti, M, Riva, A, Morazzoni, P, Donati, MB, Bombardelli, E, D'Incalci, M & Giavazzi, R 2000, 'IDN5109, a taxane with oral bioavailability and potent antitumor activity', Cancer Research, vol. 60, no. 4, pp. 842-846.
Nicoletti MI, Colombo T, Rossi C, Monardo C, Stura S, Zucchetti M et al. IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Research. 2000 Feb 15;60(4):842-846.
Nicoletti, Maria Ines ; Colombo, Tina ; Rossi, Cosmo ; Monardo, Caterina ; Stura, Stefania ; Zucchetti, Massimo ; Riva, Antonella ; Morazzoni, Paolo ; Donati, Maria Benedetta ; Bombardelli, Ezio ; D'Incalci, Maurizio ; Giavazzi, Raffaella. / IDN5109, a taxane with oral bioavailability and potent antitumor activity. In: Cancer Research. 2000 ; Vol. 60, No. 4. pp. 842-846.
@article{72d7d99d4ccb4df6b594a35574f887e1,
title = "IDN5109, a taxane with oral bioavailability and potent antitumor activity",
abstract = "IDN5109 is a new taxane, derived from 14β-hydroxy-10-deacetylbaccatin III, selected for its lack of cross-resistance in tumor cell lines expressing the multidrug resistant phenotype. Because, unlike paclitaxel, IDN5109 is a poor substrate for P-glycoprotein, we hypothesized that IDN5109 given p.o. could improve bioavailability compared with paclitaxel. Here, we studied the p.o. and i.v. pharmacokinetics of IDN5109 together with its antitumor activity. Using a high-performance liquid chromatography method, the bioavailability of IDN5109 was determined to be 48{\%} after oral delivery. IDN5109 given p.o. was highly active against the two human ovarian carcinoma xenografts 1A9 and HOC18 (90-100{\%} tumor regressions) and showed significant activity on the paclitaxel-resistant MNB-PTX1 xenograft (10{\%} tumor regressions). The p.o. administration was as active as the i.v. route at doses reflecting the pharmacokinetic data. IDN5109 is the first taxane with good oral bioavailability and potent antitumor activity and represents a potential candidate for clinical investigation.",
author = "Nicoletti, {Maria Ines} and Tina Colombo and Cosmo Rossi and Caterina Monardo and Stefania Stura and Massimo Zucchetti and Antonella Riva and Paolo Morazzoni and Donati, {Maria Benedetta} and Ezio Bombardelli and Maurizio D'Incalci and Raffaella Giavazzi",
year = "2000",
month = "2",
day = "15",
language = "English",
volume = "60",
pages = "842--846",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - IDN5109, a taxane with oral bioavailability and potent antitumor activity

AU - Nicoletti, Maria Ines

AU - Colombo, Tina

AU - Rossi, Cosmo

AU - Monardo, Caterina

AU - Stura, Stefania

AU - Zucchetti, Massimo

AU - Riva, Antonella

AU - Morazzoni, Paolo

AU - Donati, Maria Benedetta

AU - Bombardelli, Ezio

AU - D'Incalci, Maurizio

AU - Giavazzi, Raffaella

PY - 2000/2/15

Y1 - 2000/2/15

N2 - IDN5109 is a new taxane, derived from 14β-hydroxy-10-deacetylbaccatin III, selected for its lack of cross-resistance in tumor cell lines expressing the multidrug resistant phenotype. Because, unlike paclitaxel, IDN5109 is a poor substrate for P-glycoprotein, we hypothesized that IDN5109 given p.o. could improve bioavailability compared with paclitaxel. Here, we studied the p.o. and i.v. pharmacokinetics of IDN5109 together with its antitumor activity. Using a high-performance liquid chromatography method, the bioavailability of IDN5109 was determined to be 48% after oral delivery. IDN5109 given p.o. was highly active against the two human ovarian carcinoma xenografts 1A9 and HOC18 (90-100% tumor regressions) and showed significant activity on the paclitaxel-resistant MNB-PTX1 xenograft (10% tumor regressions). The p.o. administration was as active as the i.v. route at doses reflecting the pharmacokinetic data. IDN5109 is the first taxane with good oral bioavailability and potent antitumor activity and represents a potential candidate for clinical investigation.

AB - IDN5109 is a new taxane, derived from 14β-hydroxy-10-deacetylbaccatin III, selected for its lack of cross-resistance in tumor cell lines expressing the multidrug resistant phenotype. Because, unlike paclitaxel, IDN5109 is a poor substrate for P-glycoprotein, we hypothesized that IDN5109 given p.o. could improve bioavailability compared with paclitaxel. Here, we studied the p.o. and i.v. pharmacokinetics of IDN5109 together with its antitumor activity. Using a high-performance liquid chromatography method, the bioavailability of IDN5109 was determined to be 48% after oral delivery. IDN5109 given p.o. was highly active against the two human ovarian carcinoma xenografts 1A9 and HOC18 (90-100% tumor regressions) and showed significant activity on the paclitaxel-resistant MNB-PTX1 xenograft (10% tumor regressions). The p.o. administration was as active as the i.v. route at doses reflecting the pharmacokinetic data. IDN5109 is the first taxane with good oral bioavailability and potent antitumor activity and represents a potential candidate for clinical investigation.

UR - http://www.scopus.com/inward/record.url?scp=17344393983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344393983&partnerID=8YFLogxK

M3 - Article

C2 - 10706091

AN - SCOPUS:17344393983

VL - 60

SP - 842

EP - 846

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 4

ER -